Expression of Endothelin-1, Endothelin Receptor-A, and Endothelin Receptor-B in facial melasma compared to adjacent skin.
endothelin receptor-A
endothelin receptor-B
endothelin-1
immunofluorescence technique
melasma
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
28
09
2023
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Although melasma is highly prevalent, its pathogenesis is not yet fully understood. In the skin, endothelin-1 (ET-1) is primarily produced by keratinocytes in response to UVB exposure, which is mediated by an increase in IL-1α or reactive oxygen species. ET-1 plays a role in melanogenesis by binding to specific receptor B (ERB) or receptor A (ERA). However, the expression of ET-1, ERA, and ERB in melasma has not been systematically investigated. The objective of this study was to evaluate the expression of ET-1, ERA, and ERB in facial melasma compared to the adjacent unaffected skin. Cross-sectional study, with 40 skin samples (20: facial melasma; 20: adjacent unaffected skin) from women with facial melasma without treatment for 30 days except for sunscreen. A triple staining immunofluorescence technique was performed for anti-vimentin, DAPI, plus one of the following antibodies: (a) anti-ET1, (b) anti-ERA; (c) anti-ERB. Interfollicular areas on the slides of each topography (melasma; unaffected skin) were photographed in triplicate under confocal laser microscopy. The mean staining intensities of the image histograms (0-255 pixels intensity) were estimated for different types of cells (suprabasal keratinocytes, basal layer, and upper dermis) and were blindly compared between topographies. The mean (SD) age of the participants was 44.9 (9.2). The expression of ET-1 was increased in the whole epidermis with melasma when compared to the adjacent skin, being 32.8% (CI95% 14.7%-52.6%) higher in the spinous layer (p=0.013), 30.4% (CI95% 13.7%-47.9%) higher in the basal layer (p=0.014), and 29.7% (CI95% 11.4%-49.7%) higher in the melanocytes (p=0.006). There was no noticeable expression of ET-1 within the cells on the upper dermis. Neither ERA nor ERB resulted in differential epidermal expression between melasma and unaffected skin (p≥0.1). ET-1 is expressed more intensely on the epidermis from the skin with facial melasma compared to the unaffected adjacent skin.
Sections du résumé
Background/Objectives
UNASSIGNED
Although melasma is highly prevalent, its pathogenesis is not yet fully understood. In the skin, endothelin-1 (ET-1) is primarily produced by keratinocytes in response to UVB exposure, which is mediated by an increase in IL-1α or reactive oxygen species. ET-1 plays a role in melanogenesis by binding to specific receptor B (ERB) or receptor A (ERA). However, the expression of ET-1, ERA, and ERB in melasma has not been systematically investigated. The objective of this study was to evaluate the expression of ET-1, ERA, and ERB in facial melasma compared to the adjacent unaffected skin.
Methods
UNASSIGNED
Cross-sectional study, with 40 skin samples (20: facial melasma; 20: adjacent unaffected skin) from women with facial melasma without treatment for 30 days except for sunscreen. A triple staining immunofluorescence technique was performed for anti-vimentin, DAPI, plus one of the following antibodies: (a) anti-ET1, (b) anti-ERA; (c) anti-ERB. Interfollicular areas on the slides of each topography (melasma; unaffected skin) were photographed in triplicate under confocal laser microscopy. The mean staining intensities of the image histograms (0-255 pixels intensity) were estimated for different types of cells (suprabasal keratinocytes, basal layer, and upper dermis) and were blindly compared between topographies.
Results
UNASSIGNED
The mean (SD) age of the participants was 44.9 (9.2). The expression of ET-1 was increased in the whole epidermis with melasma when compared to the adjacent skin, being 32.8% (CI95% 14.7%-52.6%) higher in the spinous layer (p=0.013), 30.4% (CI95% 13.7%-47.9%) higher in the basal layer (p=0.014), and 29.7% (CI95% 11.4%-49.7%) higher in the melanocytes (p=0.006). There was no noticeable expression of ET-1 within the cells on the upper dermis. Neither ERA nor ERB resulted in differential epidermal expression between melasma and unaffected skin (p≥0.1).
Conclusion
UNASSIGNED
ET-1 is expressed more intensely on the epidermis from the skin with facial melasma compared to the unaffected adjacent skin.
Identifiants
pubmed: 37850109
doi: 10.2147/CCID.S402168
pii: 402168
pmc: PMC10578179
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2847-2853Informations de copyright
© 2023 da Silva et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Br J Dermatol. 2018 Mar;178(3):632-639
pubmed: 28494100
J Cell Biol. 1988 Oct;107(4):1611-9
pubmed: 2459134
An Bras Dermatol. 2022 Sep-Oct;97(5):575-582
pubmed: 35840442
J Physiol. 2016 Jun 15;594(12):3439-52
pubmed: 26846374
J Cosmet Dermatol. 2021 Aug;20(8):2531-2537
pubmed: 33355986
Int J Cosmet Sci. 2015 Apr;37(2):222-8
pubmed: 25439299
Front Cell Dev Biol. 2022 Sep 02;10:961675
pubmed: 36120581
Basic Res Cardiol. 2013 Mar;108(2):335
pubmed: 23381122
Indian J Dermatol Venereol Leprol. 2021 Apr 12;:1-3
pubmed: 33871200
J Vasc Bras. 2017 Apr-Jun;16(2):88-91
pubmed: 29930631
Arch Dermatol Res. 2020 Apr;312(3):223-227
pubmed: 31531731
J Biol Chem. 1992 Dec 5;267(34):24675-80
pubmed: 1280264
Exp Dermatol. 2005 Jul;14(7):528-34
pubmed: 15946241
J Invest Dermatol. 2015 Dec;135(12):3096-3104
pubmed: 26308584
Arch Dermatol Res. 2021 Oct;313(8):705-706
pubmed: 33638665
Biol Open. 2015 Sep 04;4(10):1213-21
pubmed: 26340945
J Invest Dermatol. 2020 Mar;140(3):702-706.e2
pubmed: 31476318
Br J Dermatol. 2001 Dec;145(6):895-903
pubmed: 11899142
Ann Dermatol. 2020 Apr;32(2):101-108
pubmed: 33911720
Springerplus. 2013 Nov 18;2:614
pubmed: 24303338
Front Endocrinol (Lausanne). 2019 Oct 25;10:725
pubmed: 31708873
J Vasc Bras. 2018 Oct-Dec;17(4):275-279
pubmed: 30787944
iScience. 2022 Feb 04;25(3):103871
pubmed: 35252805
Int J Mol Sci. 2023 Apr 18;24(8):
pubmed: 37108635
Life Sci. 2012 Oct 15;91(13-14):628-33
pubmed: 22483687
An Bras Dermatol. 2020 Nov - Dec;95(6):684-690
pubmed: 33010989
In Vitro Cell Dev Biol Anim. 2016 Aug;52(7):749-56
pubmed: 27130676
J Invest Dermatol. 2004 May;122(5):1256-65
pubmed: 15140230
Clin Exp Dermatol. 2016 Jul;41(5):480-5
pubmed: 27135282
J Invest Dermatol. 1993 Jan;100(1):23-6
pubmed: 8423387
Br J Dermatol. 1996 Dec;135(6):918-23
pubmed: 8977712
Front Genet. 2016 Aug 17;7:146
pubmed: 27582758
J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S439-42
pubmed: 15838343
Allergy. 2018 Feb;73(2):511-515
pubmed: 28960333
Anal Quant Cytopathol Histpathol. 2014 Oct;36(5):245-57
pubmed: 25803996
Photochem Photobiol Sci. 2013 Jan;12(1):54-64
pubmed: 23111621
Int J Cosmet Sci. 2018 Aug;40(4):420-424
pubmed: 29846953
Exp Physiol. 2000 Nov;85(6):839-46
pubmed: 11187978
J Invest Dermatol. 1995 Dec;105(6):744-8
pubmed: 7490466
Dermatol Ther (Heidelb). 2022 Sep;12(9):1967-1988
pubmed: 35904706
J Dermatol. 2009 Jan;36(1):10-6
pubmed: 19207431
J Vasc Bras. 2021 Jul 05;20:e20210038
pubmed: 34267792
Arthritis Rheum. 2010 Mar;62(3):878-89
pubmed: 20131241
Cells. 2022 Dec 07;11(24):
pubmed: 36552713
J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1254-62
pubmed: 19486232
J Invest Dermatol. 1995 Jul;105(1):32-7
pubmed: 7615973
Pigment Cell Res. 2004 Apr;17(2):96-110
pubmed: 15016298
Am J Pathol. 2004 Dec;165(6):2099-109
pubmed: 15579452
J Clin Invest. 1997 Feb 15;99(4):635-42
pubmed: 9045865